GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concerns from U.S. and European regulators.
The post Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision appeared first on MedCity News.
Arrests made after teenager killed in crash
A man and a woman have been arrested on suspicion of causing death by dangerous driving after a teenager was killed in Bedfordshire, police said.
